This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
2 May 2012

LifeCodexx Completes Clinical Validation of Noninvasive Prenatal Test Method of Trisomy 21

LifeCodexx has announced the successful completion of the clinical validation study of its noninvasive test method for the detection of fetal trisomy 21 from maternal blood using Next Generation sequencing.

LifeCodexx AG has announced the successful completion of the clinical validation study of its noninvasive test method for the detection of fetal trisomy 21 from maternal blood using Next Generation sequencing.

 

First results from the prospective blinded multi-center study demonstrate highest clinical accuracy for the planned commercial PraenaTest? test design based on Cell-Free DNA? blood collection tubes (BCT), detecting all positive cases of fetal trisomy 21 (100% sensitivity) with no false negative calls (100% specificity).

 

During the study, five prenatal centers and university hospitals in Germany and Switzerland recruited a total of 522 maternal blood samples from pregnant women with high risk of chromosomal alterations in the unborn child. Gestational

Related News